In PD, abnormal accumulation of ceramides is associated with α-synuclein aggregation, and genetic mutations in glucocerebrosidase (GBA1), a key enzyme in sphingolipid metabolism, are among the strongest risk factors for developing PD [104]. Here, GBA1 is linked to Parkinson disease.